1. Home
  2. Live Updates
  3. Neuroendocrine tumor program

Live Breaking News & Updates on Neuroendocrine tumor program

Stay informed with the latest breaking news from Neuroendocrine tumor program on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Neuroendocrine tumor program and stay connected to the pulse of your community

Shaping the Future of Neuroendocrine Tumor Management

Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center and collaborators provide clinicians with the

United-states , Miami , Florida , American , Aman-chauhan , Chanjuan-shi , University-of-miami-miller-school-medicine , American-neuroendocrine-tumor-society , National-cancer-database , American-joint-committee-on-cancer , American-college-of-surgeons , Neuroendocrine-tumor-program

New guidelines shape the future of neuroendocrine tumor management

New guidelines shape the future of neuroendocrine tumor management
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United-states , Florida , Miami , American , Aman-chauhan , Chanjuan-shi , National-cancer-database , University-of-miami-miller-school-medicine , American-joint-committee-on-cancer , Sylvester-comprehensive-cancer-center , American-neuroendocrine-tumor-society , Neuroendocrine-tumor-program

Shaping the Future of Neuroendocrine Tumor Management

Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center and collaborators provide clinicians with the

Florida , United-states , Miami , American , Chanjuan-shi , Aman-chauhan , Sylvester-comprehensive-cancer-center , American-joint-committee-on-cancer , American-college-of-surgeons , Neuroendocrine-tumor-program , American-neuroendocrine-tumor-society , National-cancer-database

Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC

Daneng Li, MD, discusses a study utilizing of ADG126 in combination with pembrolizumab for patients with microsatellite stable colorectal cancer.

Daneng-li , Department-of-medical-oncology , Neuroendocrine-tumor-program , Medical-oncology ,

Dr Li on Frontline Treatment Considerations With IO-Based Combinations in Unresectable HCC

Daneng Li, MD, discusses considerations when choosing between treatment with immuno-oncology-based combination regimens or single-agent TKIs in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma, highlighting which patient and disease factors influence these decisions.


Daneng-li , Neuroendocrine-tumor-program , Department-of-medical-oncology-therapeutics-research , Medical-oncology , Therapeutics-research , Updates-on-progress-made-in-the-hcc-treatment-paradigm , Onclive-tv , Publications ,

Ongoing Research Could Add to Atezolizumab/Bevacizumab Backbone in First-Line Treatment of Unresectable HCC

Daneng Li, MD, discusses the current options available for the frontline treatment of patients with unresectable HCC, factors to consider when selecting a treatment regimen for this patient population, how Child-Pugh B score and bleeding could affect these decisions, and ongoing research using the atezolizumab/bevacizumab backbone in novel combinations.

California , United-states , Daneng-li , Neuroendocrine-tumor-program-at-city-of-hope , Department-of-medical-oncology-therapeutics-research , Medical-oncology , Therapeutics-research , Neuroendocrine-tumor-program , Unresectable-hcc , Child-pughb-score , Atezolizumab-bevacizumab- , D

Rapidly Expanding Treatment Armamentarium Improves Outcomes and Instills Hope in Patients With GI Cancers

Daneng Li, MD, highlights the importance of biomarker testing in gastroesophageal and biliary tract cancers, the potential role for targeted therapy in first-line CRC treatment, and when to choose neoadjuvant therapy over upfront surgery and adjuvant therapy in pancreatic cancer.

California , United-states , Vincent-chung , Richardt-lee , Marwan-fakih , Afsaneh-barzi , Daneng-li , Neuroendocrine-tumor-program-at-city-of-hope , Department-of-medical-oncology-therapeutics-research , Science-summit , Medical-oncology , Therapeutics-research

Dr. Li on the Potential For First-Line Triplet Therapy in HCC

Daneng Li, MD, discusses the investigation of triplet combination therapy for patients with hepatocellular carcinoma in the phase 1/2 Morpheus-Liver study.

Daneng-li , Neuroendocrine-tumor-program , Department-of-medical-oncology-therapeutics-research , Medical-oncology , Therapeutics-research , City-of-hope , Gastrointestinal-cancer , Gi-cancer , Onclive-tv ,

Dr Li on the Evolution of HER2-Targeted Therapy in HER2+ CRC

Daneng Li, MD, discusses the evolution of treating patients with HER2-positive colorectal cancer and highlights the effects of implementing HER2-targeted therapy in this patient population.

Daneng-li , Neuroendocrine-tumor-program , Department-of-medical-oncology-therapeutics-research , Medical-oncology , Therapeutics-research , City-of-hope , Onclive-tv , Colorectal-cancer ,

Novartis reports 'clinically relevant' survival data for Lutathera

The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours - News - PharmaTimes

United-states , American , Jonathan-strosberg , Neuroendocrine-tumor-program-at-moffitt-cancer-center , American-society-of-clinical-oncology , Novartis , Section-head , Neuroendocrine-tumor-program , Moffitt-cancer , Clinical-oncology , Annual-meeting , Lutathera